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Edward D. Verrier, MD
Two fundamental issues are raised by publicationof the article titled “Minimally Invasive Port-
Access Mitral Valve Surgery,” by Professor Mohr
and associates from the University of Leipzig (see
page 567). First, should The Journal of Thoracic and
Cardiovascular Surgery and other surgical journals
publish “learning curve/feasibility” results after the
introduction of a new surgical technology? Second,
how should medicine, or cardiothoracic surgery in
particular, safely introduce new technology into the
competitive marketplace at a time when evidence
based, outcome measured results are increasingly
demanded by insurers, government agencies, and
patients?
In regard to the first question, I believe the
Journal has a responsibility to publish not only
scientifically valid basic science research and pro-
spective randomized clinical trials, but also articles
that might affect safety and efficacy issues, even if
not optimally designed. If one looks at articles
published in the cardiothoracic literature histori-
cally and more recently, the majority of articles
remain retrospective reviews, personal series, case
reports, or megaanalyses. Technology evolves so
rapidly that by the time a prospective randomized
trial might be designed and carried out, the variables
have changed and the results are no longer applica-
ble.
The presentation of Professor Mohr’s experience
with Port-Access mitral valve surgery at the 1997
meeting of The American Association for Thoracic
Surgery, along with the publication of the abstract,
may have already contributed to the dramatic im-
provements in results. Abstracts submitted for re-
cent cardiothoracic surgery and cardiology meetings
have documented dramatically better results with
the Port-Access technology and have identified a
number of critical issues: (1) There is a learning
curve, so training is essential; (2) femoral artery and
groin wound complications do occur, and local
vascular reconstruction after cannula removal must
be meticulous; (3) the descending aorta presents
potentially lethal complications if not investigated
before the operation (by transesophageal echocar-
diography or computed tomographic scanning) and
respected during the operation; (4) neuropsycho-
logic complications are not decreased with endovas-
cular aortic occlusion and probably occur at a higher
incidence because of inadequate deairing, endovas-
cular manipulation, retrograde aortic perfusion, and
balloon manipulation in close proximity to the aortic
arch; (5) endoaortic balloon migration is common,
may be difficult to deal with during the operation,
and is potentially dangerous; (6) mitral valve disease
must be carefully assessed to avoid a high reopera-
tive rate (6/51 patients in the present study); (7)
respiratory management must be conducted aggres-
sively in the postoperative period to avoid prolonged
ventilatory management; (8) at present, this partic-
ular operative method should not be chosen on the
basis of presumed reduction in cost.
Surgeons considering using the Port-Access sys-
tem, or any unfamiliar surgical technique, for that
matter, must be aware of all potential complications
and have strategies developed in advance to avoid
complications or to deal with them if they arise. A
report such as Professor Mohr’s assists surgeons in
developing these strategies and therefore is a valu-
able part of the medical literature.
With regard to the second question, as a specialty
we must think through the issues that apply to
advances in surgical techniques. If we look at our
specialty in historic terms, modern cardiac surgery is
about fifty years old and thus is still in its infancy.
Major changes have come rapidly with the introduc-
tion of cardiopulmonary bypass, myocardial revas-
cularization, valve replacement and repair tech-
niques, and more recently minimally invasive
surgical approaches, transmyocardial laser revascu-
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larization, and ventricular reduction surgery. Such
rapid and impressive advances may not have oc-
curred if the medical society, insurance companies,
and government agencies demanded that every in-
novation undergo the scrutiny of a prospective
randomized trial. Coronary artery bypass grafting
underwent such scrutiny (albeit expensive and labor
intensive) with the Coronary Artery Surgery Study
(CASS),1 funded by the National Institutes of
Health, and the European Coronary Artery Surgery
Study Group,2 and these studies continue to define
today’s standards for coronary artery bypass surgery.
However, most of the techniques used in modern
cardiac surgery were not subjected to randomized
trials but nonetheless have been carefully scruti-
nized and are continually being refined. Indeed, the
early advances in cardiac surgery occurred because
innovative surgeons were willing to “push the enve-
lope.” Certainly the invasive cardiology community
has little regulation as they introduce new catheter-
based approaches on what seems like a monthly
basis. The bottom line, however, is that our popula-
tion is living longer than ever before, and much of
that longevity has been due to advances in treating
the number one killer—heart disease.
The other side of the coin reflects the recent
pressure within the United States scientific commu-
nity (National Institutes of Health), governmental
regulatory agencies (Food and Drug Administra-
tion, Health Care Financing Administration), and
purchasers of care (Medicare, Blue Cross/Blue
Shield) demanding evidence-based outcomes
analysis.3 Such analysis is viewed as critical before
the release of certain new technologies and in
many instances before authorizing payment. This
process of regulation has gone on for a number of
years but is accentuated by managed care priori-
ties and the health care spending crisis.4 The more
common cardiac surgery procedures have become
standardized, providing a benchmark for compar-
ison of newer procedures and technologies. These
standards will be increasingly used by both the
scientific community and purchasers of health
care to judge the safety, efficacy, and utility of new
developments.
In recent years there has been a subtle but real
pressure to discourage clinical innovations in the
United States for a variety of complex reasons. The
end result, however, is that most of the clinical
advances in cardiothoracic surgery have originated
outside the United States (the Jatene operation for
transposition, the Carpentier operations for mitral
valve disease, the Fontan operation for single ven-
tricle physiology, the David operation for aortic
valve repair, the Batista operation for cardiomyop-
athy, and others). Even the present series, presented
by Mohr and associates, originates from Europe.
More recently, authorization for payment in the
Medicare population has been withheld for
transmyocardial laser revascularization and reduc-
tion ventriculoplasty pending more definitive out-
comes analyses showing not only feasibility but also
safety and efficacy. Despite widespread press in the
lay literature and promotion by aggressive surgeons
looking to increase market share, clinical innova-
tions will increasingly be scrutinized before wide-
spread acceptance or payment will occur. The con-
tinued development of minimally invasive cardiac
surgery will depend on finding a middle ground
between the forces that encourage innovation and
advancement and those that repress it.
The debate over minimally invasive surgery will
continue, and I suspect these techniques will be
modified and improved and ultimately will find a
clinical niche. All of us in cardiothoracic surgery
should critically review these technologic advances
with a thoughtful and responsible approach to max-
imize clinical results for our individual patients. Do
not use these innovative techniques for the wrong
reasons. Experience and patient selection will be
critical to obtaining excellent results. Use all meth-
ods of communication, such as our thoracic journals,
formal society-sponsored meetings, industry-spon-
sored workshops, the Internet, and personal com-
munication to form a solid foundation before insti-
tuting such programs. Finally, we must be respectful
of our surgical heritage and support clinical innova-
tion that is done responsibly and for the right
reasons.
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